1. Home
  2. HTD vs PHAR Comparison

HTD vs PHAR Comparison

Compare HTD & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HTD
  • PHAR
  • Stock Information
  • Founded
  • HTD 2004
  • PHAR 1988
  • Country
  • HTD United States
  • PHAR Netherlands
  • Employees
  • HTD N/A
  • PHAR N/A
  • Industry
  • HTD Finance Companies
  • PHAR Biotechnology: Pharmaceutical Preparations
  • Sector
  • HTD Finance
  • PHAR Health Care
  • Exchange
  • HTD Nasdaq
  • PHAR Nasdaq
  • Market Cap
  • HTD 863.8M
  • PHAR 951.7M
  • IPO Year
  • HTD N/A
  • PHAR N/A
  • Fundamental
  • Price
  • HTD $24.72
  • PHAR $13.14
  • Analyst Decision
  • HTD
  • PHAR Strong Buy
  • Analyst Count
  • HTD 0
  • PHAR 3
  • Target Price
  • HTD N/A
  • PHAR $30.00
  • AVG Volume (30 Days)
  • HTD 92.3K
  • PHAR 11.1K
  • Earning Date
  • HTD 01-01-0001
  • PHAR 11-06-2025
  • Dividend Yield
  • HTD 8.59%
  • PHAR N/A
  • EPS Growth
  • HTD N/A
  • PHAR N/A
  • EPS
  • HTD N/A
  • PHAR N/A
  • Revenue
  • HTD N/A
  • PHAR $339,836,000.00
  • Revenue This Year
  • HTD N/A
  • PHAR $17.70
  • Revenue Next Year
  • HTD N/A
  • PHAR $12.25
  • P/E Ratio
  • HTD N/A
  • PHAR N/A
  • Revenue Growth
  • HTD N/A
  • PHAR 22.44
  • 52 Week Low
  • HTD $16.17
  • PHAR $7.31
  • 52 Week High
  • HTD $22.13
  • PHAR $17.08
  • Technical
  • Relative Strength Index (RSI)
  • HTD 50.30
  • PHAR 43.07
  • Support Level
  • HTD $24.46
  • PHAR $13.08
  • Resistance Level
  • HTD $25.20
  • PHAR $14.10
  • Average True Range (ATR)
  • HTD 0.29
  • PHAR 0.53
  • MACD
  • HTD -0.04
  • PHAR -0.15
  • Stochastic Oscillator
  • HTD 46.07
  • PHAR 6.18

About HTD John Hancock Tax Advantaged Dividend Income Fund of Beneficial Interest

John Hancock Tax-advantaged Div Inc Fd is a closed-end, diversified management investment company. Its investment objective is to provide a high after-tax total return from dividend income and capital appreciation. The fund's portfolio composition consists of common stocks, preferred securities, corporate bonds, convertible bonds, and short-term investments. Its sector composition comprises utilities, financials, energy, telecommunication services, industrials, healthcare, real estate, consumer discretionary and short-term investments.

About PHAR Pharming Group N.V.

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

Share on Social Networks: